JP2023501317A5 - - Google Patents
Info
- Publication number
- JP2023501317A5 JP2023501317A5 JP2022525916A JP2022525916A JP2023501317A5 JP 2023501317 A5 JP2023501317 A5 JP 2023501317A5 JP 2022525916 A JP2022525916 A JP 2022525916A JP 2022525916 A JP2022525916 A JP 2022525916A JP 2023501317 A5 JP2023501317 A5 JP 2023501317A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- cell lymphoma
- formula
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930208P | 2019-11-04 | 2019-11-04 | |
| US62/930,208 | 2019-11-04 | ||
| PCT/EP2020/080493 WO2021089419A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023501317A JP2023501317A (ja) | 2023-01-18 |
| JP2023501317A5 true JP2023501317A5 (enExample) | 2023-10-13 |
| JP7575454B2 JP7575454B2 (ja) | 2024-10-29 |
Family
ID=73043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525916A Active JP7575454B2 (ja) | 2019-11-04 | 2020-10-30 | Ｂ細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220401442A1 (enExample) |
| EP (1) | EP4054582B1 (enExample) |
| JP (1) | JP7575454B2 (enExample) |
| KR (1) | KR20220098175A (enExample) |
| CN (1) | CN114728003B (enExample) |
| AU (1) | AU2020381240C1 (enExample) |
| CA (1) | CA3158321A1 (enExample) |
| DK (1) | DK4054582T3 (enExample) |
| ES (1) | ES3055126T3 (enExample) |
| FI (1) | FI4054582T3 (enExample) |
| MX (1) | MX2022005250A (enExample) |
| PL (1) | PL4054582T3 (enExample) |
| PT (1) | PT4054582T (enExample) |
| WO (1) | WO2021089419A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| KR20250105657A (ko) * | 2022-11-15 | 2025-07-08 | 아스트라제네카 아베 | 카피바설팁과 베네토클락스의 치료적 조합 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| EP3689878B1 (en) | 2011-07-19 | 2021-10-06 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| KR20160090903A (ko) * | 2013-12-04 | 2016-08-01 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| CN105979948A (zh) * | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
| US20180353512A1 (en) * | 2015-06-23 | 2018-12-13 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
| US20170071962A1 (en) * | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
| CU20180059A7 (es) * | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2019058348A1 (en) * | 2017-09-25 | 2019-03-28 | Astrazeneca Ab | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
-
2020
- 2020-10-30 EP EP20800617.1A patent/EP4054582B1/en active Active
- 2020-10-30 MX MX2022005250A patent/MX2022005250A/es unknown
- 2020-10-30 PT PT208006171T patent/PT4054582T/pt unknown
- 2020-10-30 FI FIEP20800617.1T patent/FI4054582T3/fi active
- 2020-10-30 DK DK20800617.1T patent/DK4054582T3/da active
- 2020-10-30 WO PCT/EP2020/080493 patent/WO2021089419A1/en not_active Ceased
- 2020-10-30 US US17/755,548 patent/US20220401442A1/en active Pending
- 2020-10-30 KR KR1020227018891A patent/KR20220098175A/ko active Pending
- 2020-10-30 JP JP2022525916A patent/JP7575454B2/ja active Active
- 2020-10-30 ES ES20800617T patent/ES3055126T3/es active Active
- 2020-10-30 CN CN202080076132.6A patent/CN114728003B/zh active Active
- 2020-10-30 AU AU2020381240A patent/AU2020381240C1/en active Active
- 2020-10-30 PL PL20800617.1T patent/PL4054582T3/pl unknown
- 2020-10-30 CA CA3158321A patent/CA3158321A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2757373C2 (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| EP1339399B1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
| JP2012500180A5 (enExample) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| WO2010081817A1 (en) | Method for treating colorectal cancer | |
| US7846913B2 (en) | Compositions and methods to treat recurrent medical conditions | |
| CN110013478A (zh) | 用于抗肿瘤试剂施用的方法 | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| JP2024542984A5 (enExample) | ||
| JP2010538066A5 (enExample) | ||
| JP2023501317A5 (enExample) | ||
| JP2024517085A5 (enExample) | ||
| HUP0204139A2 (en) | Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease | |
| JP2023522415A5 (enExample) | ||
| CN105101968A (zh) | 治疗增殖性疾病的组合疗法 | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| KR20240069750A (ko) | 신경 장애의 치료 | |
| US20080207644A1 (en) | Therapeutic materials and methods | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| FI4054582T3 (fi) | Akalabrutinibin ja kapivasertibin terapeuttisia yhdistelmiä b-solumaligniteettien hoitoon | |
| JP2006508118A5 (enExample) | ||
| JP7824627B2 (ja) | 癌療法のためのイアダデムスタット（ｉａｄａｄｅｍｓｔａｔ）の組み合わせ物 | |
| CN100553634C (zh) | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 | |
| EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
| RU2320344C2 (ru) | Применение 4-пиридилметилфталазинов для лечения рака |